We are a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases. Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders.
Psychedelic drugs were used by doctors for treating and numbing patients with mental health. But with the lack of knowledge about the dosage and effects, these treatments made these drugs un-effective. Bright Minds Biosciences have identified the natural properties of psychedelic drugs and create next generation psychedelic which is more effective.
/image%2F6304363%2F20210225%2Fob_c47acc_clock-5701307-1280.jpg)
/image%2F6304363%2F20210222%2Fob_7ae4f0_man-4075279-1280.jpg)
/image%2F6304363%2F20210222%2Fob_66cb76_biotechnology-company-bright-minds.jpg)
/image%2F6304363%2F20210218%2Fob_315e03_drugdeveloper-brightminds.jpg)